Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Differences in chest HRCT findings in relation to ANCA subtypes in ANCA-associated vasculitis.

Respiratory investigation·2026

Same author

Micro-computed tomographical and histopathological analyses of medial tibial plateaus from patients with subchondral insufficiency fracture or osteoarthritis of the knee.

Arthritis research & therapy·2026

Same author

Editor's Note: Expression of Snail in Upper Urinary Tract Urothelial Carcinoma: Prognostic Significance and Implications for Tumor Invasion.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

Delayed Bone Fracture Healing in Hybid (Hyaluronan-Binding Protein Involved in Hyaluronan Depolymerization)-Deficient Mice.

The American journal of pathology·2025

Same author

The Involvement of HYBID in the Regulation of Intraocular Pressure and Extracellular Matrix Accumulation in the Trabecular Meshwork.

Biological & pharmaceutical bulletin·2025

Same author

Bone marrow lesion coexisted with subchondral bone attrition and/or subchondral bone cyst is associated with knee pain in knee osteoarthritis regardless of cartilage lesion: the Bunkyo health study.

Arthritis research & therapy·2025

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

ADAM28 as a target for human cancers.

Satsuki Mochizuki¹, Yasunori Okada

¹Department of Pathology, School of Medicine, Keio University, Tokyo, Japan. smochi@sc.itc.keio.ac.jp

Current Pharmaceutical Design

|July 16, 2009

Summary

ADAM28, a metalloproteinase, is overexpressed in lung and breast cancers, correlating with proliferation and metastasis. Its activity and gene expression are discussed as potential cancer therapeutic targets.

Area of Science:

Biochemistry
Molecular Biology
Oncology

Background:

ADAM28 belongs to the ADAM (a disintegrin and metalloproteinase) gene family, with two known isoforms.
It possesses a metalloproteinase domain with catalytic activity and a disintegrin domain that interacts with specific integrins.

Purpose of the Study:

To review data on proADAM28 activation and tissue localization in human cancers.
To discuss ADAM28's regulation, functions in cancer, and potential as a therapeutic target.

Main Methods:

Review of existing data on ADAM28.
Analysis of ADAM28 expression and function in human cancers.

Main Results:

ADAM28 is overexpressed in human non-small cell lung and breast carcinomas.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: Jun 21, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Expression correlates with increased carcinoma cell proliferation and lymph node metastasis.

Conclusions:

ADAM28 plays a significant role in human cancer progression.
ADAM28 represents a potential therapeutic target for various cancers.